The White House has indicated President Donald Trump will sign legislation introduced by U.S. Rep. John Katko to crack down on synthetic drugs, according to a statement of administration policy released Wednesday.
Katko's bill, the Stop the Importation and Trafficking of Synthetic Analogues Act, would establish a new schedule under the Controlled Substances Act for synthetic compounds. The measure would also add 13 fentanyl compounds to Schedule A, the new schedule that would be created.
In the statement of administration policy, the Trump administration said Katko's legislation would "strengthen the ability of federal law enforcement to defend our borders against criminals who ship drugs onto our soil."
Statements of administration policy are typically issued to indicate whether the president's advisers would recommend whether he should sign or veto bills advancing in Congress.
The statement regarding Katko's bill concludes with a sentence revealing that the president's advisers would recommend Trump sign the legislation.
Entering 2018, the legislation has been one of Katko's top priorities. He invited Teresa Woolson to attend Trump's State of the Union address in January. Woolson's son drowned in Lake Ontario after using synthetic drugs.
The legislation has received support from law enforcement officers, including central New York leaders. Syracuse Police Chief Frank Fowler traveled to Washington in February to testify in support of Katko's bill.
In a statement released earlier this year, Katko said his measure would "help stop the unlawful importation and distribution of synthetic drugs and give our law enforcement the tools they need to keep our community safe."
The House is expected to consider Katko's bill, which has 75 cosponsors representing both parties, on Friday. If the House passes the legislation, it must be approved by the Senate before it heads to the White House for Trump's review.